| |
|
|
|
Trillium Therapeutics Inc.  
|
|
1.67 -0.14 (-0.08%) |
01-15 16:00 |
|
Open: |
1.8 |
Pre close: |
1.81 |
Target:
|
2.25 
|
|
High: |
1.84 |
Low: |
1.62 |
Resistance:
|
1.92
2.21
|
|
Volume: |
564,446 |
Market Cap: |
25M |
Support:
|
1.46
1.21
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
1.86
|
MACD |
MACD(12,26):
|
-0.14 |
|
MA(20): |
1.81 |
Signal(12,26,9): |
-0.18  |
|
MA(100): |
3.69 |
Stochastic Oscillator |
%K(14,3):
|
39.21 |
|
MA(250): |
5.39 |
%D(3): |
57.56 |
|
Average Volume(K) |
3-Month: |
16962
|
52-Week |
High:
|
9.16 |
|
10-Days: |
34912 |
Low: |
1.46 |
|
RSI |
RSI(14):
|
37.88 |
Change(%): |
-78.7 |
|
Financials, Statistics and Valuation |
|
EPS |
0.000 |
Return on Equity (ttm) |
-627.9 |
Shares Out. (M) |
14.69 |
|
EPS Est. Current Year |
-4.130 |
Return on Assets (ttm) |
-62.5 |
Shares Float (M) |
14.69 |
|
EPS Est. Next Year |
-2.740 |
PEG Ratio |
0.00 |
% Held by Insiders |
0.00 |
|
EPS Est. Next Quarter |
-0.960 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
53.40 |
|
Forward EPS |
-2.917 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
0 |
|
Book Value (p.s.) |
22.740 |
EBITDA (p.s.) |
0.000 |
P/E |
0.00 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
0.07 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-28.14 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-17.55 |
P/CF |
-0.87 |
|
|
|
|
|
|
